Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice.

We have generated transgenic mice expressing the human apolipoprotein CII (apoCII) gene under the transcriptional control of the human cytochrome P-450 IA1 (CYPIA1) promoter. Human apoCII transgenic (HuCIITg) mice exhibited significant basal expression of the transgene (plasma apoCII level = 26.1 +/- 4 mg/dl) and showed further induction of transgene expression after treatment with beta-naphthoflavone. Unexpectedly, HuCIITg mice were hypertriglyceridemic and human apoCII levels correlated strongly to triglyceride levels (R = 0.89, P < 0.0001). Triglyceride levels (mg/dl +/- SEM) were elevated compared to controls in both the fed (804 +/- 113 vs 146 +/- 18, P < 0.001) and fasted (273 +/- 39 vs 61 +/- 4, P < 0.001) states. HuCIITg mice accumulated triglyceride-rich very low density lipoproteins (VLDL) with an increased apoC/apoE ratio. Tracer kinetic studies indicated delayed clearance of VLDL-triglyceride, and studies using Triton inhibition of VLDL clearance showed no increase in VLDL production. Plasma from these mice activated mouse lipoprotein lipase normally and radiolabeled VLDL were normally hydrolyzed. However, HuCIITg VLDL showed markedly decreased binding to heparin-Sepharose, suggesting that apoCII-rich, apoE-poor lipoprotein may be less accessible to cell surface lipases or receptors within their glycosaminoglycan matrices. HuCIITg mice are a promising model of hypertriglyceridemia that suggests a more complex role for apoCII in the metabolism of plasma triglycerides.

[1]  Y. Zhu,et al.  Localization of a liver-specific enhancer in the apolipoprotein E/C-I/C-II gene locus. , 1993, Journal of lipid research.

[2]  R. Mahley,et al.  Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. , 1993, The Journal of biological chemistry.

[3]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[4]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[5]  S. Santamarina-Fojo.  Genetic dyslipoproteinemias: role of lipoprotein lipase and apolipoprotein C-ll , 1992 .

[6]  R. Hegele,et al.  Interaction between variant apolipoproteins C-II and E that affects plasma lipoprotein concentrations. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[7]  J. Taylor,et al.  Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. , 1991, The Journal of biological chemistry.

[8]  R. Mahley,et al.  Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. , 1990, The Journal of biological chemistry.

[9]  J. Breslow,et al.  Accumulation of human apolipoprotein E in the plasma of transgenic mice. , 1990, The Journal of biological chemistry.

[10]  J. Breslow,et al.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. , 1990, Science.

[11]  D. Nebert,et al.  Cell-specific induction of mouse Cyp1a1 mRNA during development. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Breslow,et al.  High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. , 1989, The Journal of biological chemistry.

[13]  C. Fielding,et al.  A change in apolipoprotein B expression is required for the binding of apolipoprotein E to very low density lipoprotein. , 1988, The Journal of biological chemistry.

[14]  W. Meyers,et al.  Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase. , 1987, The American journal of physiology.

[15]  M. Kawakami,et al.  Plasma apolipoprotein CII levels in hypertriglyceridemia. , 1986, Metabolism: clinical and experimental.

[16]  D. Nebert,et al.  Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. , 1985, Nucleic acids research.

[17]  R. Havel,et al.  Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. , 1985, Journal of lipid research.

[18]  S. Quarfordt,et al.  Apolipoprotein effects on the lipolysis of perfused triglyceride by heparin-immobilized milk lipase. , 1985, The Journal of biological chemistry.

[19]  N. Le,et al.  Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss. , 1985, The Journal of clinical investigation.

[20]  C. L. Jackson,et al.  Isolation and sequence of a human apolipoprotein CII cDNA clone and its use to isolate and map to human chromosome 19 the gene for apolipoprotein CII. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Shirai,et al.  Interaction of lipoprotein lipase with phospholipid vesicles. Role of apolipoprotein C-II and heparin. , 1981, Biochimica et biophysica acta.

[22]  Y. Chao,et al.  Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. , 1980, The Journal of biological chemistry.

[23]  W. Meyers,et al.  Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. , 1980, The Journal of clinical investigation.

[24]  J. Little,et al.  Inheritance of apolipoprotein C-II deficiency with hypertriglyceridemia and pancreatitis. , 1978, The New England journal of medicine.

[25]  H. Freeze,et al.  A comparison of molecular properties of hepatic triglyceride lipase and lipoprotein lipase from human post-heparin plasma. , 1978, The Journal of biological chemistry.

[26]  R. Havel,et al.  Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. , 1973, Biochemistry.

[27]  W. Brown,et al.  Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. , 1972, Biochemical and biophysical research communications.

[28]  J. Larosa,et al.  A specific apoprotein activator for lipoprotein lipase. , 1970, Biochemical and biophysical research communications.

[29]  K. Weber,et al.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. , 1969, The Journal of biological chemistry.

[30]  G. R. Bartlett.  Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.

[31]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[32]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[33]  T. Leff,et al.  Regulation of cytochrome P450 in cultured human colonic cells. , 1993, Archives of biochemistry and biophysics.

[34]  D. Rosenberg.  Dietary modulation of cytochrome P450 in the small intestinal epithelium. , 1991, Pharmacology.

[35]  D. Rosenberg,et al.  Tissue-specific induction of the carcinogen inducible cytochrome P450 isoform, P450IAI, in colonic epithelium. , 1991, Archives of biochemistry and biophysics.

[36]  C. S. Wang,et al.  Structure and functional properties of apolipoprotein C-II. , 1991, Progress in lipid research.

[37]  A. Okey.  Enzyme induction in the cytochrome P-450 system. , 1990, Pharmacology & therapeutics.

[38]  J. Whitlock.  The regulation of cytochrome P-450 gene expression. , 1986, Annual review of pharmacology and toxicology.